HER 2/NEU oncoprotein: a biomacker in human prostate cancer

ABSTRACT

To determine the frequencies of HER-2/neu overexpression in prostate adenocarcinoma. A retrospective study of 50 patients suffering from prostate adenocarcinoma. BMSI, Jinnah Post Graduate Medical Centre Karachi 1999-2001. Fifty patients between the ages of 50-80 years were selected during period 1990-2001 having prostate carcinoma. Maximum numbers of tumour among total cases were in age group ranging from 51-60 years i.e.13 tumours [26% of total cases]. Frequency of HER/2neu expression was found to be 12%. All the positive cases were poorly differentiated with Gleason score 8-10. HER-2/neu overexpression was present in 12% of prostatic adenocarcinoma cases. Specific therapeutic targeting of these neoplasms may be accomplished with [Herceptin], which may reveal a new treatment option